Antibe Therapeutics Faces FDA Hold and Legal Challenges
Company Announcements

Antibe Therapeutics Faces FDA Hold and Legal Challenges

Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.

Antibe Therapeutics Inc. is facing a setback as the FDA has placed a clinical hold on their lead drug, otenaproxesul, delaying the start of Phase II trials. Concurrently, the company is dealing with legal action from Nuance Pharma Limited, which is enforcing an arbitration award and seeking the appointment of a receiver in Ontario. To manage these challenges, Antibe is establishing an Executive Committee to coordinate operational and governance matters.

For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistATBPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TipRanks Canadian Auto-Generated NewsdeskAntibe Therapeutics Faces Receivership and Delisting
TipRanks Canadian Auto-Generated NewsdeskAntibe Therapeutics Seeks Crucial Stay Extension
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App